kl340399
Small moleculeexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 31, 2022 (NCT05387928)
Timeline
2020s
- Jan 1, 2022
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
STING1 agonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05549804 | Phase 1 | Aug 30, 2022 | Peking University, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
| NCT05387928 | Phase 1 | May 31, 2022 | Peking University, Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Sichuan Kelun Pharmaceutical Research Institute Co., Ltd. | For profit | 2 | 2 | 1 | 2022 |
2 organizations
Page 1 / 1